[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2006291568A1 - Inhibition of viral gene expression using small interfering RNA - Google Patents

Inhibition of viral gene expression using small interfering RNA Download PDF

Info

Publication number
AU2006291568A1
AU2006291568A1 AU2006291568A AU2006291568A AU2006291568A1 AU 2006291568 A1 AU2006291568 A1 AU 2006291568A1 AU 2006291568 A AU2006291568 A AU 2006291568A AU 2006291568 A AU2006291568 A AU 2006291568A AU 2006291568 A1 AU2006291568 A1 AU 2006291568A1
Authority
AU
Australia
Prior art keywords
seq
sequence
shrna
rna
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006291568A
Other languages
English (en)
Inventor
Heini Ilves
Brian H. Johnston
Roger L. Kaspar
Attila A. Seyhan
Alexander V. Vlassov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somagenics Inc
Original Assignee
Somagenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/032768 external-priority patent/WO2006031901A2/fr
Application filed by Somagenics Inc filed Critical Somagenics Inc
Publication of AU2006291568A1 publication Critical patent/AU2006291568A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006291568A 2005-09-12 2006-06-01 Inhibition of viral gene expression using small interfering RNA Abandoned AU2006291568A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/US2005/032768 2005-09-12
PCT/US2005/032768 WO2006031901A2 (fr) 2004-09-10 2005-09-12 Petits arn interferents inhibant efficacement l'expression genique virale et methodes d'utilisation associees
PCT/US2006/021253 WO2007032794A2 (fr) 2005-09-12 2006-06-01 Inhibition de l'expression genique virale a l'aide d'un petit arn interferent

Publications (1)

Publication Number Publication Date
AU2006291568A1 true AU2006291568A1 (en) 2007-03-22

Family

ID=37708176

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006291568A Abandoned AU2006291568A1 (en) 2005-09-12 2006-06-01 Inhibition of viral gene expression using small interfering RNA

Country Status (9)

Country Link
EP (1) EP1979480A2 (fr)
JP (1) JP2009521207A (fr)
KR (1) KR20090003147A (fr)
CN (2) CN101305095B (fr)
AU (1) AU2006291568A1 (fr)
BR (1) BRPI0615717A2 (fr)
CA (1) CA2622242A1 (fr)
RU (1) RU2008114304A (fr)
WO (1) WO2007032794A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042115A2 (fr) * 2007-09-24 2009-04-02 Rosetta Inpharmatics Llc Procédés de mise au point d'arn en épingle à cheveux courts (arnsh) pour le silençage de gènes
EP2341943B1 (fr) * 2008-09-22 2018-11-07 Dicerna Pharmaceuticals, Inc. Compositions et procédés pour inhiber spécifiquement de l'expression d'un gène par modifications du traitement de l'arnds
EP2352744B1 (fr) * 2008-10-15 2016-09-21 Somagenics, Inc. Arn courts en épingles à cheveux destinés à inhiber l'expression des gènes
CA3151965A1 (fr) * 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Agents allonges servant de substrats de dicer et procedes d'inhibition specifique de l'expression d'un gene
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
DK2606134T3 (da) * 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
KR101668954B1 (ko) 2015-05-29 2016-10-24 연세대학교 산학협력단 ＨＣＶ ＩＲＥＳ를 표적으로 하는 Ｃ형 간염 바이러스 치료제 siRNA
CN110462042B (zh) 2016-12-15 2023-10-27 梅哈里医学院 抗病毒剂
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
CA3106701A1 (fr) 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. Compositions d'agent d'arndb du virus de l'hepatite b (vhb) et leurs methodes d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517427A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＣ型肝炎ウイルス（ＨＣＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP1793835A4 (fr) * 2004-09-10 2010-12-01 Somagenics Inc Petits arn interferents inhibant efficacement l'expression genique virale et methodes d'utilisation associees
CN100344331C (zh) * 2004-09-22 2007-10-24 广州拓谱基因技术有限公司 用于预防或治疗丙型肝炎的靶向小干扰rna制剂及其制备方法

Also Published As

Publication number Publication date
KR20090003147A (ko) 2009-01-09
RU2008114304A (ru) 2009-11-20
CA2622242A1 (fr) 2007-03-22
WO2007032794A2 (fr) 2007-03-22
EP1979480A2 (fr) 2008-10-15
JP2009521207A (ja) 2009-06-04
CN101305095B (zh) 2012-09-26
CN101305095A (zh) 2008-11-12
BRPI0615717A2 (pt) 2011-05-24
CN102827841A (zh) 2012-12-19
WO2007032794A3 (fr) 2007-08-30

Similar Documents

Publication Publication Date Title
US7902351B2 (en) Inhibition of viral gene expression using small interfering RNA
AU2006291568A1 (en) Inhibition of viral gene expression using small interfering RNA
Kronke et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs
AU2005240118C1 (en) Methods and compositions for reducing viral genome amounts in a target cell
US10982212B2 (en) Conserved HBV and HCV sequences useful for gene silencing
Vlassov et al. shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA
US20100063132A1 (en) Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
Sim et al. RNA interference against enterovirus 71 infection
Chevalier et al. Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs
Yi et al. Replication of subgenomic hepatitis A virus RNAs expressing firefly luciferase is enhanced by mutations associated with adaptation of virus to growth in cultured cells
Kim et al. Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model
Jarczak et al. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons
EP2316942B1 (fr) Sequences vhb et vhc conservees utilisees pour un silençage genique
Zekri et al. Consensus siRNA for inhibition of HCV genotype-4 replication
US20090318531A1 (en) Small Interfering RNA Specific For HCV And Therapeutic Agent For Hepatitis C Comprising The Same
Wilson et al. Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV
MX2008003504A (en) Inhibition of viral gene expression using small interfering rna
Shier et al. Effect of RNA interference on the hepatitis C virus core expression in HepG2/C3A cells using genotype 4 isolates from Saudi patients
Ding et al. Stably silencing of CD81 expression by small interfering RNAs targeting 3'-NTR inhibits HCV infection
Scott Inhibition of Rift Valley Fever virus using RNA interference technology
Gromeier et al. The Polypyrimidine Tract Binding Protein Is
AU2011250867A1 (en) Methods and compositions for reducing viral genome amounts in a target cell

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application